Skip to Content
Get key facts and figures about chronic dry eye

Xalatan (latanoprost ophthalmic) Disease Interactions

There are 3 disease interactions with Xalatan (latanoprost ophthalmic):

Moderate

Ophthalmic Pg Analogues (Includes Xalatan) ↔ Macular Edema

Moderate Potential Hazard, Moderate plausibility

Applies to: Pseudophakia, Retinal Disorder

Macular edema, including cystoid macular edema, has been reported during treatment with ophthalmic prostaglandin analogues. Most cases occurred in patients with aphakia, pseudophakia with a torn posterior lens capsule, or known risk factors for macular edema (e.g., posterior uveitis, certain retinal disorders). Therapy with ophthalmic prostaglandin analogues should be administered cautiously in these patients.

References

  1. "Product Information. Lumigan (bimatoprost ophthalmic)" Allergan Inc, Irvine, CA.
  2. "Product Information. Travatan (travoprost ophthalmic)" Alcon Laboratories Inc, Fort Worth, TX.
  3. "Product Information. Xalatan (latanoprost ophthalmic)." Pharmacia and Upjohn, Kalamazoo, MI.
Moderate

Ophthalmic Pg Analogues (Includes Xalatan) ↔ Uveitis

Moderate Potential Hazard, Moderate plausibility

Applies to: Uveitis

Bimatoprost, latanoprost, and travoprost are synthetic prostaglandin analogues. Theoretically, these agents may mimic endogenous prostaglandins and mediate ocular inflammatory responses. In clinical trials, uveitis and iritis have been reported rarely. Therapy with ophthalmic prostaglandin analogues should be administered cautiously in patients with active intraocular inflammation.

References

  1. "Product Information. Xalatan (latanoprost ophthalmic)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. "Product Information. Travatan (travoprost ophthalmic)" Alcon Laboratories Inc, Fort Worth, TX.
  3. "Product Information. Lumigan (bimatoprost ophthalmic)" Allergan Inc, Irvine, CA.
Moderate

Ophthalmic Pgf2A Analogues- Renal/Liver Disease

Moderate Potential Hazard, Low plausibility

Applies to: Liver Disease, Renal Dysfunction

Prostaglandin F2-alpha analogues are hydrolyzed by esterases in the cornea to their corresponding active free acid form, which is absorbed systemically and metabolized by the liver via fatty acid beta-oxidation, then eliminated by the kidney. These agents have not been adequately studied in the treatment of patients with impaired renal and/or hepatic function. Therapy with ophthalmic prostaglandin F2-alpha analogues should be administered cautiously in such patients.

References

  1. "Product Information. Xalatan (latanoprost ophthalmic)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. "Product Information. Travatan (travoprost ophthalmic)" Alcon Laboratories Inc, Fort Worth, TX.

Xalatan (latanoprost ophthalmic) drug Interactions

There are 2 drug interactions with Xalatan (latanoprost ophthalmic)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide